Overall safety margin : The , supporting a reasonable safety window for first‑in‑human (FIH) dosing.
Systemic accumulation of toxic aldehydes is a known driver of fibrotic progression in organs like the liver and kidneys. Researchers are investigating whether ALDN-084 can slow down or reverse tissue scarring in conditions such as Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) or chronic kidney disease. 4. Preclinical and Clinical Development Status ALDN-084
The potential applications of ALDN-084 are vast and varied, spanning multiple fields of research. Some possible areas of investigation include: Overall safety margin : The , supporting a